PTGX vs ZBH
Protagonist Therapeutics, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
PTGX
Protagonist Therapeutics, Inc.
65
Buy
VS
| Metric | PTGX | ZBH |
|---|
| AI Score |
65
|
69
|
| Price |
$148.25
|
$97.22
|
| P/E Ratio |
121.74×
|
23.54×
|
| ROE |
-21.2%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.9%
|
69.9%
|
| Debt / Equity |
0.01×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
68.1
|
63.1
|
| Beta |
1.794
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for PTGX versus ZBH.
ZBH leads by 4 points.
ZBH scores 69/100 (Buy) versus PTGX at 65/100 (Buy).
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical